East Japan Railway Company: Releasing the Welcome Suica Mobile App for Overseas Visitors to Japan
24.3.2025 15:00:00 CET | Business Wire | Press release
Travel Japan with a single app!
JR East has released the Welcome Suica Mobile app for overseas visitors to Japan on Thursday, March 6, 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310510899/en/
service banner
The app allows users to issue and top up their Suica in the app without going to a ticket office or vending machine at the station both before and after entering Japan; is accepted on trains, buses and other public transportation; and can even be used for shopping.
In fall 2025, the app will be connected to JR-EAST Train Reservation to enable the use of Shinkansen e-ticket and conventional line limited express ticketless service, with purchase of Green Car seats on local trains to be made available in spring 2026. Expanding services provide even more ways for our international visitors to enjoy seamless, ticketless transportation while in Japan.
1. App Release Date
Approx. 10:00 AM JST, Thursday, March 6, 2025 (tent.)
2. App Overview
Name: Welcome Suica Mobile
Language: English
Supported Devices: iPhone, Apple Watch
* Some iOS or watchOS versions may not be compatible.
Reference: Differences Between Welcome Suica Mobile and Welcome Suica (card)
| Welcome Suica Mobile | Welcome Suica |
Personalization | Non-personalized | Non-personalized |
SF / e-money | ✓ | ✓ |
Passes | ✓ | ✓ |
Stored Fare (SF) refunds | ×* | ×* |
Suica expiration date | 180 days from issuance | 28 days from first use |
Topping up |
|
|
Deposit | Not required | Not required |
Legend: ✓: Supported ×: Not supported *Remaining balance is non-refundable. SF expires on Suica expiration date. | ||
3. Key Features
Based on the service concept, “Travel Japan with a single app!”, Welcome Suica Mobile can be used for riding trains, buses and other public transportation, making purchases in stores that accept e-money, and even provides information for tourist attractions and transfer directions to support travel in Japan.
Official service website: https://www.jreast.co.jp/multi/wsmlp/
- Images are for illustrative purposes only and are subject to change.
- Apple, the Apple logo, Apple Pay, iPhone and Apple Watch are registered trademarks of Apple Inc. in the U.S. and other countries.
- The iPhone trademark is used under license from Aiphone Co., Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250310510899/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
Roboverse Reply Impresses at ELROB 2026 With Intelligent Robotic Systems for Critical Missions26.6.2026 10:00:00 CEST | Press release
Roboverse Reply, the Reply Group company specializing in robotics and automation, won the 1st Place in the “Reconnaissance” category and a special prize for “Best Team Effort” at the European Land Robot Trial (ELROB) 2026 in Thun, Switzerland. Teaming up with ELP, a specialist for technical equipment for defusing service, the company demonstrated outstanding performance alongside a field of international participants from June 15 to 19, proving that its autonomous solutions operate reliably under real-world conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626012237/en/ Roboverse Reply won 1st Place in the “Reconnaissance” category and a special prize for “Best Team Effort” at the European Land Robot Trial 2026, proving that its autonomous solutions operate reliably under real-world conditions. ELROB is Europe’s most demanding and established showcase for robotics and unmanned systems, where leading experts from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom